ResApp Health Limited (ASX: RAP), the developer of smartphone medical applications for the diagnosis and management of respiratory disease, today announced that it has entered into a two-year expanded research collaboration with Massachusetts General Hospital (MGH) alongside MGH’s participation in ResApp’s SMARTCOUGH-C study. Working together, ResApp and MGH will perform additional analysis of the SMARTCOUGH-C study data, use the SMARTCOUGH-C dataset to investigate the state of respiratory disease clinical practice today and evaluate the efficacy of ResApp’s cough-based diagnostic test in additional respiratory disease indications.
MGH is a 999-bed academic medical centre located in Boston, Massachusetts. MGH has been named the number one healthcare organization for research by the Nature Index which tracked the number of articles published in high-impact research journals from February 2015 to January 2016 and has been among the top hospitals each year on the U.S. News & World Report list of “America’s Best Hospitals.”
Dr. Peter Moschovis M.D., MPH will lead the team at MGH. Dr. Moschovis undertook his specialist training at Harvard Medical School and has a joint appointment in paediatrics and pulmonary/critical care at MGH. Dr. Moschovis is a global health researcher in the Division of Global Health at MGH.
“We are delighted to expand our relationship with Dr. Moschovis and MGH beyond the SMARTCOUGH-C study to diagnose additional diseases and to evaluate clinical practices. The more broadly and effectively we apply ResApp’s technology with our partners, the more rapidly we will integrate our diagnostic test into current clinical practice,” said Tony Keating, CEO and Managing Director of ResApp Health.
– ENDS –
About ResApp Health Limited
ResApp Health Limited (ASX: RAP) is a digital health company developing smartphone applications for the diagnosis and management of respiratory disease. The technology is based on machine learning algorithms that use sound alone to diagnose and measure the severity of respiratory conditions without the need for additional hardware. The algorithms were initially developed by The University of Queensland with funding from the Bill and Melinda Gates Foundation. ResApp has both adult and paediatric clinical studies underway with preliminary results demonstrating accurate diagnosis of pneumonia, asthma/viral wheeze, bronchiolitis, croup and upper respiratory tract infections in children as well as chronic obstructive pulmonary disease, asthma and pneumonia in adults. Markets for ResApp’s technology include telehealth use through partnerships with telehealth service providers, emergency department and regular clinic use by healthcare providers, at-home use by consumers and working with global aid and humanitarian organisations to deliver tools for the developing world.
For more information on ResApp, visit www.resapphealth.com.au.
ResApp Health Limited
ABN 51 094 468 318
Headquarters: Level 8, 127 Creek St, Brisbane, QLD 4000
Registered Office: Level 24, 44 St Georges Tce, Perth, WA 6000
© 2019 ResApp Health Limited. All rights reserved. US Patent No. 10,098,569, Australian Patent No. 2013239327, Japanese Patent No. 6,435,257 and Patents Pending. ResApp Health®, the ResApp Health logo and ResAppDx® are registered trademarks of ResApp Health Limited in the United States and other countries.